-
2021 - 01 - 21
Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
-
2021 - 01 - 22
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Awareness Day
-
2021 - 03 - 08
Press Release March 5th
-
2021 - 03 - 29
Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize ELZONRIS<sup>®</sup> (Tagraxofusp) in Japan
-
2021 - 04 - 08
INTERNATIONAL FAIR PLAY-MENARINI AWARDS TO CELEBRATE 25-YEAR ANNIVERSARY
-
2021 - 04 - 09
Menarini Pills of Art Junior project launched, video clips made by the younger generations for children and teenagers
-
2021 - 04 - 16
Covid-19: Menarini, new reagent made in Italy for the isolation of viral RNA
-
2021 - 05 - 14
Menarini receives the coveted M&A Award 2021 for the 2020 acquisition of US company Stemline Therapeutics
-
2021 - 05 - 24
Le Volpi Rosse Menarini Campioni d'Italia: La squadra giovanile conquista il suo primo, storico, scudetto
-
2021 - 05 - 28
Menarini Silicon Biosystems launches new breakthrough DEPArray™ PLUS image-based cell sorter to isolate rare cells with single cell precision
-
2021 - 06 - 01
Menarini Announces New SEL24/MEN1703 Clinical Data from DIAMOND-01 Trial
-
2021 - 06 - 09
Press Release June 10th
-
2021 - 06 - 11
The “youth Role model” category of the Fair Play - Menarini Award named in memory of champion footballer Paolo Rossi
-
2021 - 07 - 15
International Fair Play Menarini Award: programme and names of the winners of the xxv edition revealed
-
2021 - 09 - 02
Sporting legends shine on a magical evening at the Menarini Fair Play awards
-
2021 - 10 - 12
Antibiotic-resistance: Welcome to the "Infection in Focus" website
-
2021 - 10 - 19
Serie A: the Volpi Rosse Menarini are ready to meet the challenge
-
2021 - 10 - 20
Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
-
2021 - 11 - 04
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia
-
2021 - 11 - 30
New CELLSEARCH<sup>®</sup> Circulating Multiple Myeloma Test now available to help community physicians optimize patient care
-
2021 - 12 - 08
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
-
2021 - 12 - 13
Menarini: a gift to the Misericordia Campo di Marte to give life to their new ‘home’
-
2021 - 12 - 14
Menarini Silicon Biosystems Announces study results to be presented at American Society of Hematology (ASH) Annual Meeting
-
2021 - 12 - 16
Menarini Silicon Biosystems announces new DEPArray™ PLUS application to identify mutations in FFPE tissue samples with low tumor cellularity
-
2021 - 12 - 21
Karyopharm and Menarini Group Enter into Exclusive License Agreement to Commercialize NEXPOVIO<sup>®</sup> (selinexor) in Europe and Other Key Global Territories
-
2021 - 12 - 22
Pope Francis welcomes in audience the Fair Play Menarini Award
